IMMX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
12.5M
+15.3%
10.8M
-0.8%
10.9M
+42.2%
7.7M
+14.1%
6.7M
R&D
5.3M
-10.8%
6.0M
+4.4%
5.7M
+24.9%
4.6M
+15.4%
4.0M
SG&A
7.1M
+47.7%
4.8M
-6.6%
5.2M
+67.8%
3.1M
+12.1%
2.7M
Operating Income
-12456343
-15.3%
-10803855
+0.8%
-10893276
-42.2%
-7662509
-14.1%
-6717705
EBITDA
-12365350
-15.4%
-10712278
+1.2%
-10841162
-43.3%
-7565523
-13.6%
-6659211
Net Income
-11557002
-14.6%
-10086687
+5.6%
-10687830
-40.9%
-7585692
-14.5%
-6622563
EPS (Basic)
$-0.18
+0.0%
$-0.18
+33.3%
$-0.27
-12.5%
$-0.24
-9.1%
$-0.22
EPS (Diluted)
$-0.18
+0.0%
$-0.18
+33.3%
$-0.27
-12.5%
$-0.24
-9.1%
$-0.22
Shares (Diluted)
63.8M
+15.2%
55.4M
+37.6%
40.3M
+26.1%
31.9M
+6.5%
30.0M
Immix Biopharma (IMMX) โ€” Financials